Inventage Lab, a drug delivery platform company, announced on Monday that it will present key results from clinical trials of two long-acting injectable drug candidates at the 2026 American Academy of Neurology (AAN) meeting in Chicago, Illinois.
The AAN conference is a globally recognized event in the field of neuroscience, where pharmaceutical and biotech companies, along with researchers from around the world, gather to share their latest findings.
Inventage Lab will showcase Phase 1 clinical trial results for IVL3003 (a dementia treatment) and IVL3004 (a treatment for drug and alcohol addiction), both developed using the company’s proprietary long-acting injectable drug manufacturing platform, IVL-DrugFluidic®.
This presentation is viewed as evidence of the company’s successful expansion of its long-acting formulation platform technology into various areas of central nervous system (CNS) disorders.
In the clinical study for the dementia treatment IVL3003, researchers observed that, unlike daily oral medications, blood drug concentrations remained stable for over four weeks. Additionally, they confirmed a predictable dose-response relationship, where drug exposure in the body increased proportionally with higher doses.
The study demonstrated a consistent pharmacological response, with inhibition of acetylcholinesterase, an enzyme implicated in dementia, correlating with blood concentration levels. The level of inhibition was comparable to that observed in patients receiving repeated doses of oral Aricept.
Clinical trials of IVL3004, the drug and alcohol addiction treatment, also yielded promising results in healthy volunteers. The formulation showed no initial burst release, a common issue with some long-acting injectables. Compared to existing long-acting formulations, IVL3004 maintained stable and effective blood concentrations while demonstrating a reduced side effect profile.
Through these clinical trials, Inventage Lab has demonstrated that its long-acting formulation technology can achieve consistent release control across various drugs. The company believes this technology has the potential to significantly improve patient compliance and treatment continuity.
Dr. Kim Joo-hee, Chief Executive Officer (CEO) of Inventage Lab, stated that all three of the pipeline candidates have consistently demonstrated stable blood concentration profiles and dose-proportional characteristics in clinical trials. The fact that they’re seeing similar results across drugs with different mechanisms of action is strong evidence that the platform technology can be applied to a wide range of therapeutic areas, not just specific drugs.
Dr. Kim added that it will continue our efforts to leverage this technology to improve treatment accessibility and enhance the quality of life for patients across various disease areas.
